Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.89 |
| ▸ | FAAH | O00519 | 8/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.49 |
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17510903 | 1.00 | GAA (0.89) | GAAFAAHRECQLKMT2AMEN1 | |
| SCHEMBL12319369 | 1.00 | GAA (0.89) | GAAFAAHRECQLKMT2AMEN1 | |
| SCHEMBL12960566 | 1.00 | GAA (0.89) | GAAFAAHRECQLKMT2AMEN1 | |
| SCHEMBL17510902 | 0.97 | GAA (0.83) | GAAFAAHRECQLKMT2AMEN1 | |
| SCHEMBL20398937 | 0.92 | GAA (0.76) | GAAFAAHRECQLKMT2AMEN1 | |
| SCHEMBL20398923 | 0.92 | GAA (0.76) | GAAFAAHRECQLKMT2AMEN1 | |
| SCHEMBL20398895 | 0.92 | GAA (0.76) | GAAFAAHRECQLKMT2AMEN1 | |
| SCHEMBL20398926 | 0.92 | GAA (0.76) | GAAFAAHRECQLKMT2AMEN1 | |
| SCHEMBL20398916 | 0.92 | GAA (0.76) | GAAFAAHRECQLKMT2AMEN1 | |
| SCHEMBL20398900 | 0.92 | GAA (0.76) | GAAFAAHRECQLKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207370-B2 | Process for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester | KANEKA CORPORATION (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20100022795-A1 | Process for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester | KANEKA CORPORATION (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-2067769-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE BETA-HYDROXY-ALPHA-AMINOCARBOXYLIC ACID ESTER | Kaneka Corporation (JP) | 2009-06-10 | — | — | EP | disclosed |
| US-4016287-A | COSMETIC AND ANTIINFLAMMATORY | BOEHRINGER INGELHEIM GMBH (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022795-A1 | Process for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester | AADAT, ALAD, ALDH7A1 | GAA 762/4885FAAH 811/4885RECQL 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.